Detection Of Mutation P53 In Ovarian,Fallopian Tube And Peritoneal Fluid Of Ovarian Tumor And Its Clinical Significance

Objective :In this study, we examined the mutation of P53 in ovarian, distal tube, ascites /peritoneal washings and blood of ovarian tumors and normal patients. The P53 mutations in patients with epithelial ovarian cancer and the P53 mutation in ovarian,fallopian distal tube, peritoneal fluid and blood of the same ovarian cancer patients were analyzed. The relationship between P53 mutation and epithelial ovarian cancer was studied. To investigate the relationship between P53 mutation and epithelial ovarian cancer, to explore the origin characteristics of epithelial ovarian cancer, in order to further reveal the development mechanism of ovarian cancer and individualized diagnosis and treatment, to provide a possible theoretical basis.Methods:We Collected ovarian, distal tubal, ascites / peritoneal washings and venous blood samples from 92 ovarian tumor patients(62 cases of malignant, 12 cases of borderline tumor, 18 cases of benign tumor), 2 primary fallopian tube cancer patients and 13 salpingo-oophorectomy for non-tumor indications (including endometriosis,uterine fibroids, ovarian abscess). All the patients were treated in the tumor hospital of Yunnan Province from March 2016 to December 2016. DNA was extracted and amplified by PCR , The mutations of exon 4-9 of P53 gene were analyzed. We compared gene mutations in different tumors;Age, pathological type, "dualistic model" of carcinogenesis,clinical stage,CA125 levels and ascites cytology of epithelial pelvic carcinoma and P53 gene mutations were compared with Pearson x2 test; Finally, the mutation of P53 gene in four different tissues of the same patient was compared.Results:1? There were 27 patients had P53 mutation in all of 107 patients. Among the P53 mutation patients, there were 25 cases of pelvic epithelial malignant tumors (24 cases of primary ovarian cancer, 1 case of primary fallopian tube cancer)(25/57), 1 case of benign ovarian tumor (fibroblastoma) (1/18), 1 case of borderline ovary tumor(borderline serous cystadenoma) (1/12), non-tumor ovaries were not detected P53 mutations.There was significant difference in P53 mutation between three different tumors (P <0.05).2?Of the 27 patients with mutation,all of them exhibited a mutation within exons 5 to 8 of p53.There was only one patient with two mutations, all of others with a single mutation:Among them,24 cases were point mutations (22 cases were missense mutations, 2 cases were synonymous mutations), and 4 cases were deletion mutations; Mutation codons: mutation at codon 193 (exon 6) was detected in 3 patients, codon 273 (exon 8) was detected in 3 patients, codon 248 (exon7) was detected in 2 patients,Codon 280 (exon8) was detected in 2 patients, the remaining codon mutations were 1 case. The mutation rate of exon 8 was the highest at 28.57%(8/28), and the mutation of exon 4 was 5 cases (17.86%) ? exon 5 was 4 cases(14.29%)? exon 6 was 5 cases (17.86%) ? exon 7 was 5 cases (17.86%) .The mutation rate of exon 9 was the lowest, which was 3.57% (1/28).3? We used Pearson x2 test to analyze the correlation between P53 mutation and clinicopathological parameters of epithelial pelvic carcinoma. The results showed that P53 gene mutation was associated with pathological type,"dualistic model" of carcinogenesis,clinical stage,ascites cytology (P<0.05), And there was no statistically significant correlation with age and CA125 (P> 0.05).4?P53 gene mutation sites were different in 4 different tissues of the same patient.Ovarian tissue mutation rate was the highest, ascites / peritoneal washings and distal tube mutation rate followed, the rate of blood tissue mutation was the lowest.Conclusions:1?P53 gene mutation rate in ovarian malignant tumor was significantly higher than benign and borderline tumors, and it did not detect in normal tissue. It suggests that P53 gene mutations promote the formation of malignant tumors and play an important role in their development.2? P53 gene mutation was associated with pathological type, "dualistic model" of carcinogenesis, clinical stage, ascites cytology in epithelial pelvic carcinoma.Suggesting that P53 gene mutations in epithelial ovarian cancer with a higher degree of malignancy, more aggressive and worse long-term prognosis.3? P53 gene mutation has no statistically significant correlation with age and CA125 in epithelial pelvic carcinoma. Suggesting that P53 mutation is present in different age groups in epithelial pelvic carcinoma. P53 mutation is independent of tumor burden.4?Ovarian tissue has the higher mutation than the fallopian tube tissue. Only 3 cases of patients with P53 gene mutation in ovarian and fallopian tube, suggesting that the fallopian tube and ovarian gene mutation is not consistent.